Enhanced Opioid Antagonist Delivery Systems

The present invention relates to improved compositions and methods for opioid antagonist delivery, providing enhanced efficacy, safety, and accessibility in rescuing subjects from opioid overdose.

The original patent disclosed parenteral formulations for opioid overdose rescue, but had limitations in terms of targeted delivery, sustained release, and accessibility. The present invention addresses these limitations by introducing nanocarriers, sustained release formulations, and easy-to-use devices, providing improved efficacy and reduced side effects.

The inventive concept comprises a system for opioid overdose rescue, featuring a parenteral formulation with an aqueous solution containing about 1.5 mg of nalmefene free base and a nanocarrier for targeted delivery to the brain. The formulation can be designed to release nalmefene in a sustained manner over a period of at least 2 hours, providing prolonged protection against opioid overdose. Additionally, the composition can be combined with a peripheral opioid receptor antagonist to reduce the risk of opioid-induced constipation. The inventive concept also includes a device for opioid overdose rescue, comprising a pre-filled syringe containing the parenteral formulation, designed for easy and safe administration by a non-medical person.

The new claims introduce the use of nanocarriers for targeted delivery, sustained release formulations, and easy-to-use devices, which are not disclosed in the original patent. These features provide improved efficacy, safety, and accessibility in rescuing subjects from opioid overdose, thereby representing a non-obvious improvement over the prior art.

Alternative embodiments of the inventive concept could include the use of different nanocarriers, sustained release mechanisms, or devices for administration. Variations of the composition could include different opioid antagonists or peripheral opioid receptor antagonists, or different ratios of these components.

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the area of opioid overdose rescue. The improved efficacy, safety, and accessibility of the inventive concept could lead to increased adoption and market share, with potential applications in emergency medical services, hospitals, and community-based settings.